Clinical Study of Genakumab for Injection in Patients With Acute Gout
Status:
Active, not recruiting
Trial end date:
2022-05-28
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of single subcutaneous injection of Genakumab for
Injection in patients with acute gout
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
GeneScience Pharmaceuticals Co., Ltd.
Collaborators:
Affiliated Hospital of Nantong University Changhai Hospital Hainan General Hospital Huashan Hospital Linyi People's Hospital Shengjing Hospital The First Affiliated Hospital with Nanjing Medical University The Second Affiliated Hospital of Chongqing Medical University